Lilly's Zepbound® (tirzepatide) superior to Wegovy® …
Dec 4, 2024 · Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 receptor agonist in adults living with obesity without diabetes. INDIANAPOLIS, Dec. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today …
Lilly's tirzepatide superior to Wegovy® (semaglutide) in head-to …
Dec 4, 2024 · At 72 weeks, tirzepatide was superior to Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes.
Zepbound Helps People Lose More Weight Than Wegovy, According to Eli ...
Dec 14, 2024 · Eli Lilly’s Zepbound bested Novo Nordisk’s Wegovy in the first head-to-head trial comparing weight loss outcomes for people with obesity or overweight, according to top-line results shared by Lilly last week.
Eli Lilly's Zepbound tops Wegovy in head-to-head weight loss trial
Dec 4, 2024 · Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly...
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head …
In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy.
Big Move: Eli Lilly Offers Obesity Drug Directly to Consumers - WebMD
Jan 25, 2024 · Now, new research finds that semaglutide at the Wegovy dose (usually slightly higher than the Ozempic dose for diabetes) also has those benefits in those who don’t have a diabetes diagnosis but...
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Dec 4, 2024 · Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly...
In weight loss trial, Lilly's Zepbound tops Novo's Wegovy
Dec 4, 2024 · Eli Lilly revealed trial results that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Zepbound tops Wegovy for weight loss in Eli Lilly study
Dec 4, 2024 · Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk. Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.
Eli Lilly's Zepbound causes greater weight loss than Novo …
Dec 4, 2024 · Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections.